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Abstract Purpose: To investigate the efficient transduc-
tion of tumor cells which remains a major limitation of
cancer gene therapy.. Methods: In this study, we tested
whether treatment with antimetabolic drugs 5-FU and
hydroxyurea (HU) could improve adenovirus-mediated
gene expression in tumor cells. Results: We found that
5-FU and HU treatment significantly increased b-gal
activity in adenovirus (Ad.CMVBG)-infected human
colon carcinoma (LoVo) and hepatocellular carcinoma
(SMMC7721) cells in a dose- and time-dependent
manner. These increases were maximized at 5.01±0.42-
fold and 3.32±0.32-fold for 5-FU (50 lM), and at
6.60±0.50-fold and 4.82±0.43-fold for HU (5 mM)
treatment, respectively, after 48 h infection. Transient
increases in viral uptake, determined by real-time PCR
for viral DNA content and by confocal microscopy for
viral particles, were observed in 5-FU or HU-treated
cells that partially contribute to the overall increases of
b-gal expression. Moreover, mRNA levels for the b-gal
gene in infected cells were significantly increased in both
LoVo and SMMC7721 cells by 5-FU and HU treatment
in contrast to the inhibition of viral DNA replication
and the unchanged mRNA levels for a-actin gene. The
induction appeared to be the result of enhanced tran-
scription since b-gal mRNA half-life was not affected by
drug treatment. However, similar induction was not
detected in CMV-b-gal-expressing stable cells, suggest-
ing that an adenovirus-associated mechanism might be
involved in this induction. Conclusions: Our findings
suggest that it may be possible to improve tumor cell
transduction by adenovirus using chemotherapy.
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Abbreviations yCD: Yeast cytosine deaminase Æ
5-FC: 5-fluorocytosine Æ 5-FU: 5-fluorouracil Æ HU:
Hydroxyurea Æ b-gal: b-galactosidase Æ CMV:
Cytomegalovirus Æ Ad.CMVBG: E1-deleted adenovirus
containing b-gal gene Æ PCR: Polymerase chain
reaction Æ CAR: Coxsackie-adenovirus receptor Æ pfu:
Plaque-forming units Æ MOI: Multiplicity of
infection Æ RT-PCR: Reverse transcription-PCR Æ
DRB: 5,6-dichlorobenzimidazole Æ FACS:
Fluorescence-activated cell sorting
Introduction
E1-deleted adenovirus is the most widely used vector in
clinical trials of gene therapy because of its high effi-
ciency for gene transfer, ease of high titer production,
and relative safety [1, 2, 3, 4]. However, insufficient
transgene expression in tumors remains a key problem
[5, 6].
The combination of adenovirus gene therapy and
other therapeutic approaches, such as chemotherapy or
radiation, has been shown to improve outcomes in a
number of in vivo studies and clinical trials [7, 8, 9, 10,
11], suggesting that chemotherapeutic agents and radi-
ation can enhance adenovirus-mediated transgene
expression [12, 13, 14, 15, 16] in tumors. Whereas this
enhancement could vary among cell types or therapeutic
agents, the underlying mechanism needs to be further
investigated. As a major determinant of adenovirus
entry, cell surface CAR expression has been shown to
vary during cell cycle change in response to chemo-
therapeutic agents, leading to an increased virus uptake
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and enhanced transgene expression [12]. S/G2 arrest,
induced by many agents and by adenovirus infection
(both wild type and E1-mutant), has been demonstrated
to facilitate viral uptake and viral DNA replication [17,
18, 19, 21], thus, an enhanced transgene expression.
Our previous study demonstrated that adenovirus
carrying yCD genes selectively transduce colon carci-
noma cells and convert prodrug 5-FC to 5-FU in int-
rahepatic tumor xenografts [22]. However, the overall
efficiency of transduction for the initial viral infusion is
relatively low. In another study, we found that HU, an
agent that blocks viral DNA synthesis, greatly enhanced
adenovirus-mediated gene expression in tumor cells
(unpublished data). This prompted us to test whether 5-
FU and HU, both antimetabolic agents that affect DNA
synthesis and the cell cycle, would improve adenovirus-
mediated gene expression in tumor cells. It is particu-
larly important in our current yCD enzyme/prodrug
strategy where the converted drug as an active form (5-
FU) could potentially improve the efficiency for initial
viral infusion in intrahepatic tumors.
In this study, we demonstrated that 5-FU and HU
significantly enhanced adenovirus-mediated gene
expression in human colon and hepatocellular carci-
noma cells. The mechanisms involving viral uptake,
DNA replication, and transgene transcription were
further explored.
Materials and methods
Adenovirus vectors and agents
Ad.CMVBG, an E1-deleted recombinant adenovirus
serotype-5 vector containing b-gal gene under the con-
trol of CMV promoter, was constructed and propagated
by the Vector Core Facility of the University of Michi-
gan (Ann Arbor, Mich., USA). For virus labeling,
1·1012 particles were reacted with Cy3 dye (Amersham
Pharmacia Biotech, Piscataway, N.J., USA) in 0.1 M
sodium carbonate buffer (pH 9.3) as recommended by
the manufacturer. Labeled Ad.CMVBG (Cy3-
Ad.CMVBG) were then dialyzed against buffer con-
taining 10% glycerol, 10 mM HEPES, and 1 mM
MgCl2 (pH 7.4) using Slide-A-Lyzer (MWCO 7000,
Pierce, Rockford, Ill., USA). Aliquots were stored at
70 C in the dark. The OD600 and plaque assays were
used to measure the number of viral particles and pfu of
stocks, respectively. 5-FU and HU were obtained from
Sigma-Aldrich (St. Louis, Mo., USA) and were resus-
pended in appropriate buffer.
Cell culture, drug treatment, and virus infection
The human colon cancer cell line LoVo was purchased
from American Type Culture Collection (ATCC,
Manassas, Va., USA), and the human hepatocellular
carcinoma cell line SMMC7721 was a kind gift from
Z.Y. Tang (Liver Cancer Institute, Fudan University,
Shanghai, P.R. China) [23]. Stable cell line for LoVo and
SMMC7721 expressing b-gal (LoVo-b-gal and
SMMC7721-b-gal respectively) were established by
infecting parental LoVo and SMMC7721 cells with a
lentivirus vector containing a CMV-driven b-gal gene.
Cells were maintained in RPMI media containing 10%
FBS and antibiotics at 37 C with 5% CO2. LoVo and
SMMC7721 cells were preseeded in 24-well plates (1·105
cells/well) overnight prior to Ad.CMVBG infection
(MOI 100) in the presence or absence of 5-FU (5 lM, 25
lM, 50 lM, and 200 lM) or HU (0.5 mM, 1 mM,
5 mM, and 10 mM) for 12 h, 24 h, and 48 h. Determi-
nation of transgene expression, viral uptake, and mRNA
levels are described individually below.
Transgene expression by b-gal activity assay
LoVo and SMMC7721 cells were either pre-infected by
Ad.CMVBG for 3 h prior to removal of free virus in the
media or were infected by Ad.CMVBG for various time
points in the presence or absence of 5-FU or HU. b-gal
activities in cells were measured by b-Galactosidase En-
zyme Assay System (Promega, Madison, Wis., USA)
under the manufacture’s recommended conditions and
were quantified by the absorbance reading at 420 nm
using a SPECTRAmax PLUS384 Microplate Spectro-
photometer (Molecular Devices Corporation, Sunnyvale,
Calif., USA). Drug-induced b-gal expression, which was
further normalized by the amount of total cell lysate, is
represented as the fold increase compared to the activity
from non-drug-treated cells at each time point.
Determination of viral DNA by Real-time PCR
For virus uptake measurement, LoVo and SMMC7721
cells were pre-incubated with or without 5-FU (50 lM) or
HU (5 mM) for 36 h beforeAd.CMVBG infection for 3 h
followed by extensive washing in PBS to remove free virus
frommedia. For replication of viral DNA, cells were pre-
infected with Ad.CMVBG for 3 h followed by extensive
washing and were then incubated with 5-FU or HU for
48 h. Total cellular DNA was purified using DNeasy
Tissue Kit (Qiagen, Valencia, Calif., USA) and was as-
sessed for viral DNA by real-time PCR using primers
specific for the b-gal gene sequence (5’ primer: CAC-
GGCAGATACACTTGCTG, and 3’ primer: AT-
CGCCATTTGACCACTACC). Viral DNA copies were
calculated from a standard curve and were further nor-
malized in relative to the copy numbers for a-actin (5’
primer: CGAGATCCCTCCAAAATCAA, and 3’ pri-
mer: TGTGGTCATGAGTCCTTCCA) by the compar-
ative CT method (PE Applied Biosystems User
Bulletin#2). Drug-induced viral uptake was represented
as the fold increase in uptake compared to that of non-
drug-treated control cells. Real-time PCRwas performed
using QuantiTect SYBR Green PCR Kit (Qiagen) on the
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DNA Engine Opticon System (MJ Research, Waltham,
Mass., USA) in the reaction mixture (20 ll) consisting of
10 ll ofMaterMix, 1 ll of each primer (12.5 lM), and 1 ll
of sample. The thermal cycling conditions began with
denaturation and an enzyme activation step at 95 C for
15 min and 36 cycles at 94 C for 15 s, 53 C for 30 s, and
72 C for 30 s. Plates were read between annealing and
extension in every cycle. Themelting curvewas performed
from 50 C to 95 C at 1.0 C increments. Samples were
independently analyzed three times.
Confocal microscopy laser scanning
LoVo and SMMC7721 cells were seeded on 8-well
chamber slides (Nalge Nunc International, Naperville,
Ill., USA) at 1·104 cells/well and were incubated in the
presence or absence of 5-FU or HU for 36 h. Cells were
then incubated with Cy3-Ad.CMVBG (MOI 40) for 3 h
followed by extensive washing in PBS to remove free
viral particles. Cells were then fixed in 4% paraformal-
dehyde solution for confocal microscopy scanning. Im-
age analysis was performed using an Olympus IX SLA
Confocal Laser Scanning Biological Microscope equip-
ped with Texas Red laser guns operated by Fluoview
software FV-300 (Olympus USA, Melville, N.Y., USA).
Quantification of mRNA by Real-time RT-PCR
LoVo and SMMC7721 cells were pre-infected by
Ad.CMVBG as described above followed by incubation
in the presence or absence of 5-FU (50lM)orHU(5 mM)
for 0 h, 12 h, 24 h, and 48 h. Stable cell lines LoVo-b-gal
and SMMC7721-b-gal were treated by 5-FUorHUunder
similar condition without viral infection. Total RNAs
were purified using the RNeasy Kit in combination with
the RNase-Free DNase Set (Qiagen) to remove cellular
DNA.The level ofmRNAforb-galwas determinedby the
real-time RT-PCR performed on the DNA Engine Opti-
con System using QuantiTect SYBR Green RT-PCR kit
(Qiagen) under the conditions recommended by manu-
facturer. The reaction mixture (20 ll) consisted of 1 ll of
sample, 10 ll of Master mix (Qiagen, Germany), 0.2 ll of
QuantiTect RTMix, and 1.5 ll of each primers (12.5 lM)
described above, and proceeded through reverse tran-
scription (50 C for 30 min), initial denaturation and
enzyme activation (95 C for 15 min) and 36 PCR cycles
(94 C for 15 s, 53 C for 30 s and 72 C for 30 s). The
levels of mRNA for b-gal and a-actin were normalized by
total RNAamount andwere expressed as fold increases in
comparison with control cells.
Stability of mRNA for b-gal by measurement
of half-life
LoVo and SMMC7721 cells were pre-infected by
Ad.CMVBG for 3 h before incubation with 5-FU (50
lM) or HU (5 mM) for 48 h. Cells were then treated
with DRB (Sigma) at 100 lg/ml for 0 h, 0.5 h 1 h, 2 h,
and 3 h to stop new synthesis of all cellular mRNA prior
to total RNA isolation for the real-time RT-PCR
quantification of mRNA for b-gal and a-actin genes as
described above. The level of mRNA, normalized by
total RNAs, was determined as fold increase relative to
the level in non-DRB-treated cells at the time when
DRB treatment started (arbitrarily set as 1), and was
represented as log expression. Half-life for b-gal mRNA
was calculated from linear regression fitting curve as the
time when the value decreased by half.
Data analysis and statistics
Each experiment was performed four times (each at
triplicate). Values are expressed as means±standard
error and were compared by ANOVA analysis. Data
were considered significantly different when P <0.01.
Results
Gene expression and viral uptake induced by 5-FU
and HU in Ad.CMVBG-infected cells
LoVo and SMMC7721 cells were chosen to represent
primary liver tumors and colon cancer metastatic to the
liver.We found that b-gal expression in these cells infected
by Ad.CMVBG was significantly induced in the presence
of 5-FUorHUcomparedwith the expression in untreated
control cells in a time- and dose-dependent manner.
Inductionwas observed at 24 h of drug treatment andwas
maximized at 48 h for both 5-FU at 50 lM (5.01±0.42-
fold and 3.32±0.32-fold, respectively) and HU at 5 mM
(6.60±0.50-fold and 4.82±0.43-fold, respectively)
(Fig. 1). Such induction was not detected when lower
doses of 5-FU (5 and 25 lM) or HU (0.2 mM and 1 mM)
was used while no significant additional induction was
achieved at higher dose (200 lM of 5-FU or 10 mM of
HU) (data not shown). Therefore, 5-FUat 50lMandHU
at 5 mM, both clinically achievable concentrations, were
utilized in subsequent experiments. These results dem-
onstrated that 5-FU and HU increased transgene
expression in Ad.CMVBG-infected cells.
We wished to determine if drug-induced gene
expression was due to increased uptake of virus in cells.
To test this, LoVo and SMMC7721 cells were infected
with Ad.CMVBG, washed, exposed to drugs, and as-
sessed for intracellular viral DNA by real-time PCR. We
found that viral DNA content was modestly but signif-
icantly increased in both cell lines in response to 5-FU
(2.02±0.13-fold and 1.51±0.12-fold, respectively) or
HU (2.52±0.20-fold and 1.80±0.13-fold, respectively)
treatment (Fig. 2A). This was further supported by the
direct evidence from confocal microscopy that enhanced
total uptake of a Cy3-labelled Ad.CMVBG was ob-
served in cells pre-treated with 5-FU or HU compared to
control cells (Fig. 2B). These results demonstrated that
5-FU and HU facilitated adenovirus entry in cells.
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5-FU and HU induced b-gal expression by increasing
mRNA levels
Although these findings suggested that an increase, of
viral uptake played a role in increased gene expression,
the overall induction in b-gal activity was greater in
response to drug treatment than could be accounted for
by increased viral uptake. To determine whether other
mechanisms are involved in the induction, cells were
infected by Ad.CMVBG before incubation with drugs.
We found that b-gal activities in LoVo and SMMC7721
cells were enhanced by 48-h treatment with 5-FU
(3.50±0.30-fold and 1.82±0.15-fold, respectively) or
HU (4.52±0.35- and 2.71±0.20-fold, respectively)
compared with control group (Fig. 3A). This is consis-
tent with the induction observed when drug treatment
and virus infection were carried out simultaneously,
suggesting that drug-enhanced gene expression involved
other cellular mechanisms in addition to the increased
virus uptake. Real-time PCR analysis demonstrated
that, under control conditions, viral DNA selectively
Fig. 2 5-FU and HU increased
viral uptake in cells. LoVo and
SMMC7721 cells were pre-
incubated with or without
(control) 5-FU (50 lM) or HU
(5 mM) for 36 h prior to
AdCMVBG or Cy3-
AdCMVBG infection for 3 h
followed by extensive washing.
A Real-time PCR
determination of viral DNA
content in whole cell lysates by
amplification of the b-gal
sequence as described in
Materials and Methods. Data
are expressed as the fold
increase relative to control
groups. B Confocal microscopy
of Cy3-AdCMVBG-infected
LoVo and SMMC7721 cells
with or without drug pre-
treatment Images were
generated by Olympus IX SLA
Confocal Laser Scanning
Biological Microscope
equipped with Texas Red laser
gun (60·). *: Significantly
different from controls
(P<0.01, n=4)
Fig. 1 5-FU and HU induced b-gal activity treatment in Ad-
CMVBG-infected cells. LoVo and SMMC7721 cells in 24-well
plates (1·105 cells/well) were infected by AdCMVBG (MOI 100) in
the presence or absence (control) of 5-FU (50 lM) or HU (5 mM)
for 0 h, 12 h, 24 h, and 48 h. b-gal activities were measured from
cell lysates as described in Materials and Methods. Data are
expressed as fold increase relative to control groups for each time
point. A LoVo cells, B SMMC7721 cells. * Significantly different
from control (P <0.01, n=4)
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replicated in both LoVo and SMMC7721 cells at 48 h
after infection (1.61±0.14-fold and 3.13±0.25-fold,
respectively) compared to cellular DNA (Fig. 3B). As
expected, treatment with both 5-FU and HU signifi-
cantly inhibited viral DNA replication evidenced by the
decreased number of viral DNA copies in LoVo
(0.72±0.05-fold and 0.41±0.04-fold, respectively) and
SMMC7721 (0.63±0.08-fold and 0.32±0.04-fold,
respectively) (Fig. 3B). In contrast, b-gal mRNA levels
were greatly increased in LoVo and SMMC7721 cells in
response to 5-FU (3.25±0.3-fold and 2.02±0.18-fold,
respectively) or HU (3.94±0.25-fold and 2.55±0.20-
fold, respectively) treatment (Fig. 4A). Importantly,
drug treatment had no effect on a-actin mRNA pro-
duction in both cell lines (Fig. 4B), suggesting no overall
change in mRNA levels. Therefore, the drug-induced
b-gal activities in virus-infected cells were the results of
the elevated b-gal mRNA levels instead of an increased
viral DNA content.
To determine whether the increase in b-gal mRNA
levels was the result of enhanced transcription or of
prolonged stability, the half-life of b-gal mRNA was
assessed in the presence or absence of drug treatment.
We found that neither 5-FU nor HU treatment altered
the half-life of b-gal mRNA compared to untreated
controls in both LoVo (2.56±0.27 h, 2.48±0.31 h, and
2.75±0.23 h, respectively) and SMMC7721
(1.08±0.11 h, 1.03±0.12 h, and 1.20±0.15 h, respec-
tively) cells (Fig. 5). We also found that neither drug
altered the half-life for a-actin mRNA (data not shown).
Thus, our result indicated that the elevated mRNA
levels in response to drug treatment was not likely the
outcome of changes in mRNA turnover but the reflec-
tion of an enhanced transcription.
5-FU- and HU-induced transgene transcription
required adenovirus infection
To determine whether the drug-induced gene transcrip-
tion was associated with adenovirus infection rather
than the upregulation of CMV promoter activity, stable
cell lines expressing CMV-b-gal (LoVo-b-gal and
SMMC7721-b-gal) were compared to adenovirus-in-
fected parental cells for b-gal mRNA levels in response
to drug treatment. We found that 5-FU or HU treat-
ment significantly increased b-gal mRNA levels in virus-
infected cells in a time-dependent manner which oc-
curred at as early as 12-h incubation, and b-gal mRNA
levels were further enhanced after a 24-h incubation in
both pre-infected LoVo (2.22±0.24-fold and
2.51±0.25-fold, respectively) (Fig. 6A) and pre-infected
SMMC7721 (1.60±0.24-fold and 1.80±0.25-fold,
respectively) (Fig. 6B) in comparison with non-treated
cells. However, similar induction was not detected in
stable cell lines where CMV-b-gal gene was presented as
part of genomic DNA, suggesting that these drugs en-
hanced b-gal gene transcription through an adenovirus-
associated mechanism in infected cells.
Fig. 3 5-FU and HU inhibited viral DNA replication in Ad-
CMVBG-infected cells. LoVo and SMMC7721 cells (MOI 100 for
3 h) were pre-infected by AdCMVBG (MOI 100) for 3 h prior to
removal of free virus in media and were then incubated with 5-FU
(50 lM) or HU (5 mM) for 48 h while untreated cells were used as
controls. Cell lysates were measured for b-gal activity (b-gal assay
system) and viral DNA content (Real-time PCR by Opticon
System) as described in Materials and Methods. A b-gal activity
was expressed as fold increase relative to control groups of each cell
line. B Viral DNA copies were expressed as fold increases relative
to the amount in each cell line detected immediately after 3-h
infection (initial infection). * Significantly different from controls
(P <0.01, n=4)
Fig. 4 5-FU and HU treatment increased b-gal mRNA levels in
AdCMVBG-infected cells. Pre-infected LoVo and SMMC7721
cells were incubated with 5-FU or HU for 48 h as described in
Fig 3. Levels of mRNA were determined by real-time RT-PCR
using specific primers for b-gal or a-actin gene as described in
Materials and Methods. Data are expressed as fold increases
relative to the levels from control cells (arbitrarily set as ‘‘1’’).
A b-gal mRNA. B a-actin mRNA. * Significantly different from
controls (P <0.01, n=4)
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Discussion
In this study, we demonstrated that the antimetabolic
chemotherapeutic agents 5-fluorouracil and hydroxy-
urea enhanced adenovirus-mediated transgene expres-
sion in human colon carcinoma and hepatocellular
carcinoma cells. This induction was accompanied by
transient increases in viral uptake and was correlated to
the induction of gene transcription but not viral DNA
replication in infected cells. Our findings are potentially
important in combining adenovirus gene therapy and
chemotherapy for cancer treatment.
The mechanisms by which chemotherapeutic agents
induce adenovirus-mediated transgene expression are
complex. Although a transient increase in total viral
uptake was observed in response to 5-FU or HU treat-
ment, it did not seem to be exclusively responsible for
the overall drug-induced b-gal activity in infected cells
evidenced by our study. First, the induction of viral
uptake was less than the induction of b-gal activity in
infected cells. Second, pre-infected cells responded to
drug treatment similarly to cells without viral pre-
infection. Third, viral DNA replication was inhibited by
5-FU or HU treatment, further suggesting that the
number of viral DNA in infected cells was not a deter-
minant for the transgene expression. We also found that
other chemotherapeutic agents including aphidicolin,
doxorubicin, and etopside but not cisplatinum, carbo-
platinum, and nacodazole induced adenovirus-mediated
gene expression in various human tumor cells (data not
shown) consistent with some previous reports [12, 13, 14,
15]. Systems comparing other drugs should provide in-
sight as to whether these drugs share similar mecha-
nism(s) for inducing adenovirus gene expression.
One major finding in this study is that 5-FU and HU
enhanced transcription for transgene in adenovirus-in-
fected cells. Wild-type adenovirus induces the host cell
to enter the S phase of the cells cycle, providing an
optimal environment for viral gene expression and viral
replication [24]. We found that 5-FU or HU treatment
elicits an S phase arrest in LoVo and SMMC7721 cells
by FACS analysis (data not shown) consistent with
previous studies in other cells [25, 26]; thus, it may
provide compensatory factors for E1-mutant adenovirus
Fig. 5 5-FU and HU did not alter b-gal mRNA half-life in
AdCMVBG-infected cells. LoVo and SMMC7721 cells were pre-
infected by AdCMVBG (MOI 100) for 3 h followed by the removal
of free virus in media and continued incubation in the presence or
absence of 5-FU (5 mM) or HU (5 mM) for 48 h. Cells were then
incubated with DRB (100 lg/ml) for 0 h, 0.5 h, 1 h, 2 h, and 3 h
prior to real-time RT-PCR analysis for b-gal mRNA. The level of
mRNA for b-gal normalized to total RNAs was determined as fold
increase relative to the level in non-DRB-treated cells and is
represented as log expression. Half-life (T1/2) was calculated using
linear regression as described in Materials and Methods. A LoVo
cells. B SMMC7721 cells (n=4)
Fig. 6 5 FU and Hy induced b-gal transcription required adeno-
virus infection. LoVo and SMMC7721 cells, either parental cells
that received pre-infection of AdCMVBG (Infected) or cells stably
expressing CMV-b-gal (Stable), were incubated with 5-FU (5 mM)
or HU (5 mM) for 0 h, 12 h, and 24 h. b-gal mRNA levels were
assessed by real-time RT-PCR and were expressed as fold increase
relative to untreated control groups. A LoVo cells: B SMMC7721
cells. * Significantly different from controls (P <0.01, n=4)
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vector to improve transgene expression. In particular,
the cellular transcription factor E2F, elevated during S
phase arrest, has been implicated in activation of a
variety of adenovirus promoters as well as the major late
promoter [27, 28], leading to enhanced gene transcrip-
tion. Moreover, our study demonstrated that stable
LoVo and SMMC7721 cells expressing CMV-b-gal gene
responded to 5-FU and HU treatment by increasing
b-gal mRNA levels, although to a lesser extent than did
adenovirus-infected cells, at 48 h of incubation (data not
shown). Whether 5-FU or HU treatment may activate
CMV promoter, which has been suggested for other
chemotherapeutic agent [13], remains to be seen.
5-FU is commonly used in clinical treatments for
hepato-gastroenteric tumors. Our previous study dem-
onstrated that adenovirus containing CEA-yCD gene
selectively transduced intrahepatic colon carcinoma
metastases, leading to an efficient prodrug conversion
from 5-FC to 5-FU in tumors [22]. Our current findings
that that 5-FU and HU induced adenovirus-mediated
gene expression in human colon and hepatocellular
carcinoma cells would provide us with a new strategy for
combining traditional chemotherapy and adenovirus
gene therapy that utilizes an enzyme/prodrug approach
in the treatment of liver cancer. This is particularly
important in improving selectivity and efficacy for re-
peated adenovirus administration where a high level of
5-FU can be achieved from initial viral infusion.
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